Press Release FeedGet the RSS feed
Menu

Business Wire

Eurofins Delivers Improving Organic Growth Through 9M 2026; Remains on Track for 2026 and Mid-Term Profitability Objectives

Business Wire

LUXEMBOURG, October 21, 2026--Regulatory News:

Eurofins (Paris:ERF):

Eurofins delivered steady improvement in both organic and reported revenue growth throughout the first nine months of 2026:

  • Reported revenues in 9M 2026 totalled €5,614m, a 3.7% increase versus 9M 2025. Growth was driven by both organic growth13 and acquisitions, despite a -1.7% headwind from foreign exchange, and a -0.7% headwind from discontinuations and disposals15 as Eurofins exited certain non-core activities.

  • Organic revenue growth13 in 9M 2026 was 3.0%, and 2.9% including a -0.1% adjustment for public working days.

  • Organic revenue growth13 was 2.5% in Q1, 3.0% in Q2, and 3.5% in Q3 (and 2.6%, 2.9% and 3.2% respectively corrected for public working days), with growth increasing sequentially by 0.5% each quarter.

  • For 9M 2026:

    • In Europe, organic growth13 was 1.9% (1.6% including public working days adjustment), led by good growth in Environment Testing, and Clinical Diagnostics in France.

    • In North America, organic growth13 was 2.8% (2.8% including public working days adjustment), with a stronger third quarter including continued solid growth in the Life businesses, and improving growth across a number of categories within BioPharma.

    • In Rest of the World, organic growth13 of 9.3% (9.8% including public working days adjustment) included robust performance in Food & Feed Testing and Consumer Product Testing.

  • Eurofins' strategic growth investments continued in the first nine months of 2026, with the closure of 22 acquisitions with 2025 revenues of more than €210m (not including Element's North America Life Sciences Testing Services). Start-ups contributed 0.6% to organic growth13, with 15 new start-up laboratories and 4 blood collection points opened during the period.

  • Organic growth13 in Q3 2026 of 3.5% (3.2% including public working days adjustment) included a broad-based acceleration in BioPharma, with mid-single digit growth in BioPharma Product Testing, and Discovery & Genomics returning to positive growth. We also saw an expected improvement in the CDMO business, although other ancillary activities remain mixed.

Objectives

Eurofins is confirming its mid-term and FY 2027 objectives, as previously confirmed at the H1 2026 results presentation. For FY 2026 Eurofins is updating its objectives:

  • FY 2026 organic growth13 is likely to be below the previous mid-single-digit objective. This reflects the fact that market conditions have remained slower than normal after nine months, and that some expected clinical programmes will not restart in 2026; and as a result, organic growth13 is unlikely to reach the initial objective for the year as a whole.

  • Revenues from acquisitions in 2026 are expected to be above the previous objective of an annualised €250m, based on transactions already completed, including Element's North America Life Sciences Testing Services business.

  • For FY 2027, Eurofins expects to return to mid-single-digit organic growth13.

  • Objectives for profitability and cash flow for FY 2026 are unchanged. Eurofins continues to expect the adjusted1 EBITDA3 margin18 to show further progress towards the 2027 objective (24% remains the objective for 2027), with improvement in 2026 above FY 2025 margin18 of 22.5%.

  • Also, SDI2 at the EBITDA3 level should further decline from the FY 2025 level, and FCFF10 is expected to grow, with continued strong cash conversion.21

  1. AIAI and Multichannel Communication Come to Italian MunicipalitiesANCIcomunicare and Audiencerate launch a partnership to bring Italian municipalities a platform that simplifies data management and digital communication with citizens across all channels.
  2. AriniArini Announces Final Close of Inaugural Direct Lending Fund, Targeting Over $4 Billion of DeploymentLONDON, October 21, 2026--Arini, an alternative asset manager with $22 billion in assets under management as of 31 August 2026, today announces the final close of Arini Direct Lending Fund I. The Fund and related vehicles are targeting deployment of over $4 billion, including anticipated leverage, maki
  3. Fashion & luxurySkechers U.S.A., Inc.Skechers Wins Major Victory Against Kizik in Patent Infringement SuitMunich Court States that Kizik's Patent Infringement Case Against Skechers is "Largely Unfounded" LOS ANGELES, October 21, 2026--Skechers U.S.A., Inc. ("Skechers"), the third largest footwear company in the world and leader in hands-free footwear technology, announced today that it won a major legal an
  4. AISapia.aiSapia.ai Offers Rejected Candidates an AI Career Coach, Launching Love-jection at UNLEASH ParisUnsuccessful applicants can get free guidance on their strengths and the roles that suit them PARIS, October 21, 2026--Sapia.ai, the AI hiring platform built on transparency, fairness and trust, today launched Love-jection. The initiative lets clients offer unsuccessful applicants free access to Phai,
  5. SaaSLemFiLemFi Launches Its Biggest Product Expansion Yet Alongside a New Global Brand, ‘Ambition has no passport’LemFi launches the biggest product expansion in its history, adding UK savings, credit, and data eSIM in 100+ destinations A rebuilt app brings transfers, savings, credit and connectivity together in one platform for people building financial lives across borders New global brand, "Ambition has no passport", reflects LemF
  6. FinanceJFrog Closes the Shadow AI Blind Spot: Unveils AI-SEC to Control Every AI Agent, Skill, and Model, from Developer to ProductionNew Local Shadow AI Detection and Bring Your Own LLM Key scanning give security teams oversight of AI assets that pipeline and registry controls never reach SUNNYVALE, Calif. & BARCELONA, Spain, October 21, 2026--swampUP Europe 2026 – JFrog Ltd. (Nasdaq: FROG), the Liquid Software company and creators